Valproic Acid Software and Presentation by: Ted, Rob, Jeff, Cassie, Tristan, Korin, Ron, Gabe, Matt, Judith, Lindsay.

Slides:



Advertisements
Similar presentations
Clinical Pharmacokinetics
Advertisements

DISPOSITION OF DRUGS The disposition of chemicals entering the body (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill,
Dosage Regimen Design in Patients with Renal Insufficiency Cont’d Pharmacy 732 Winter, 2001.
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Nonlinear pharmacokinetics
One-compartment open model: Intravenous bolus administration
Laplace transformation
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
Week 4 - Biopharmaceutics and Pharmacokinetics
Pharmacokinetics Based on the hypothesis that the action of a drug requires presence of a certain concentration in the fluid bathing the target tissue.
Dose Adjustment in Renal and Hepatic Disease
Gokaraju Rangaraju College of Pharmacy
INTRAVENOUS INFUSION.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Nonlinear Pharmacokinetics
Pharmacokinetics Introduction
10/13/20151Prof. Mazen Qato. OBJECTIVES 10/13/2015Prof. Mazen Qato2.
Anticonvulsant Pharmacokinetics Dennis Mungall, Pharm.D. Director, Virtual Education, NTPD Associate Professor Pharmacy Practice Ohio State University.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
MECHANISTIC PHARMACOKINETICS: COMPARTMENTAL MODELS
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
One Compartment Open Model IV bolus
Core Concepts in Pharmacology Chapter 5 Pharmacokinetics.
The General Concepts of Pharmacokinetics and Pharmacodynamics
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
1 Single-dose kinetics Plasma [Drug] curve Upon administration [drug] plasma reaches a max Then begins to decline as the Drug is eliminated Cp max = max.
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Calculation of Doses Prof. Dr. Henny Lucida, Apt.
Clinical Pharmacokinetics of Carbamazepine
Clinical Pharmacokinetics Fundamental hypothesis: a relationship exists between the pharmacological or toxic response to a drug and the accessible concentration.
1. Fate of drugs in the body 1.1 absorption 1.2 distribution - volume of distribution 1.3 elimination - clearance 2. The half-life and its uses 3. Repeated.
Continuous intravenous infusion (one-compartment model)
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.
TDM Therapeutic Drug Monitoring
Prof. Dr. Henny Lucida, Apt
Therapeutic drug Monitoring
INTERMITTENT IV VANCOMYCIN WHAT DOSE SHOULD WE START WITH?
Clinical Pharmacokinetics of PHENYTOIN & OTHER ANTIEPILEPTICS
Clinical Pharmacokinetic Equations and Calculations
DEFINITIONS T1/2 & Tmax Cmax AUC 1st order kinetics
The General Concepts of Pharmacokinetics and Pharmacodynamics
Learning objectives To know what data is available from pharmacokinetic studies in man and how to handle it To know how to calculate the basic pharmacokinetic.
Pharmacokinetics: Digoxin Allie Punke
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
DOSAGE ADJUSTMENT IN RENAL AND HEPATIC DISEASES Course Title : Biopharmaceutics and Pharmacokinetics – II Course Teacher : Zara Sheikh.
Pharmacokinetics 3rd Lecture
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
MULTIPLE DOSAGE REGIMEN
Compartmental Models and Volume of Distribution
Anticonvulsants: Phenytoin
Pharmacokinetics of Vancomycin in Adult Oncology Patients
Lecture-8 Biopharmaceutics
Drug Therapy in Geriatric Patients
Controls and Functions
Anticonvulsants: Valproic acid
Pharmaceutics 2.
Pharmacokinetics.
Clinical Pharmacokinetics
School of Pharmacy, University of Nizwa
A. Domínguez-Gil Hurlé, A. Sánchez Navarro, M.J. García Sánchez 
1 Concentration-time curve
School of Pharmacy, University of Nizwa
Therapeutic Drug Monitoring chapter 1 part 1
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

Valproic Acid Software and Presentation by: Ted, Rob, Jeff, Cassie, Tristan, Korin, Ron, Gabe, Matt, Judith, Lindsay

General Information Used in the management of multiple seizure types. Used in the management of multiple seizure types. Oral and IV forms Oral and IV forms Also indicated for management of bipolar affective disorder and possible migraine prevention. Also indicated for management of bipolar affective disorder and possible migraine prevention. Increases body’s production and response to GABA. Increases body’s production and response to GABA.

Therapeutic / Toxic Conc’s Cp ss range- 50 to 100 mcg/ml. Cp ss range- 50 to 100 mcg/ml. Upper limit of 175mcg/ml with proper monitoring. Upper limit of 175mcg/ml with proper monitoring. At concentrations >75 mcg/ml some patients may experience adverse effects. At concentrations >75 mcg/ml some patients may experience adverse effects.

Basic Clinical Pharmacokinetics Exhibits concentration dependant protein binding Exhibits concentration dependant protein binding Follows Non-Linear Kinetics Follows Non-Linear Kinetics Highly protein bound to albumin Highly protein bound to albumin Follows a basic 1-Compartment Model. Follows a basic 1-Compartment Model.

Clinical Implications Clearance is now dose or concentration dependant. Clearance is now dose or concentration dependant. Volume of Distribution is now affected by concentration-dependant plasma protein binding and its value should be 0.15 to 2.0 L/kg. Volume of Distribution is now affected by concentration-dependant plasma protein binding and its value should be 0.15 to 2.0 L/kg. Half Life 12 to 18 hrs for adults and is found by the eqn. t 1/2 =0.693xVd/Cl Half Life 12 to 18 hrs for adults and is found by the eqn. t 1/2 =0.693xVd/Cl

Software Structure Functional components of the software were segmented into “tiers” to make the application to support ease of use and maintainability Functional components of the software were segmented into “tiers” to make the application to support ease of use and maintainability Core Core Peripheral Peripheral Variable Variable Core

Core Components Contains foundational assumptions of the software Contains foundational assumptions of the software User Input requirements User Input requirements Kinetic Models Kinetic Models Changing the Core will cause global changes to functionality and require massive reworking of the system Changing the Core will cause global changes to functionality and require massive reworking of the system Intolerant to changes Intolerant to changes Core

Peripheral Components Contains slowly changing parameters Contains slowly changing parameters Changes cascade to most sections of the software Changes cascade to most sections of the software Changes tolerated, but should be rare and hidden from most users Changes tolerated, but should be rare and hidden from most users Provides extensibility of the application Provides extensibility of the application Includes reports charts, kinetic parameters Includes reports charts, kinetic parameters Core

Variable Components Continuously changing Continuously changing High tolerance to changes, incorrect / inappropriate input High tolerance to changes, incorrect / inappropriate input Patient Cases Patient Cases Core

Bayesian Pharmacokinetics Estimate drug dosage or steady state plasma concentration Estimate drug dosage or steady state plasma concentration Patient’s parameters (age, weight, sex, serum creatine) Patient’s parameters (age, weight, sex, serum creatine) Absence of or with measured drug levels Absence of or with measured drug levels DrugCalc shareware software DrugCalc shareware software Dr. Dennis Mungall Dr. Dennis Mungall Nonlinear regression Nonlinear regression One-compartment model One-compartment model

DrugCalc Example Enter patient’s demographic, drug dosing, and serum concentration Enter patient’s demographic, drug dosing, and serum concentration Compute the pharmacokinetic parameters Compute the pharmacokinetic parameters Compute desired dose to achieve steady state concentration Compute desired dose to achieve steady state concentration

Example time